On April 18, 2018 Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT), a clinicalstage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, reported that preclinical data supporting the clinical development of its BET inhibitor CK-103 (also known as TG-1601) will be presented today in a poster session at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in Chicago, Illinois, at McCormick Place North/South (Press release, Checkpoint Therapeutics, APR 18, 2018, View Source [SID1234525506]). The Company’s poster is available for viewing today from 8:00 a.m. to 12:00 p.m. CT, during the Experimental and Molecular Therapeutics/Canonical Targets 2 Session in Exhibit Hall A.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Key conclusions from the poster are as follows:
TG-1601 is a novel BET inhibitor with strong binding affinity and long-lasting effect in preclinical models
• CK-103 is a novel and potent BET inhibitor that specifically inhibits the binding of the BET subfamily of bromodomain-containing protein family;
• CK-103 potently inhibits cell growth of various multiple myeloma and lymphoma cell lines in vitro, but does not affect the growth of normal cell lines;
• CK-103 inhibits MYC and Bcl-2 expression in preclinical models; and
• CK-103 showed combinatorial effects in an in vivo model with anti-PD-1 antibodies.
James F. Oliviero, President and Chief Executive Officer of Checkpoint, said, "These data demonstrate CK103’s
potential to be a novel BET inhibitor that potently inhibits MYC expression. Elevated levels of MYC proteins are found in 60-70% of all cancers, making this family of oncogenes a promising therapeutic target. We believe the preclinical data presented today provides encouraging evidence to support the development of CK-103 as an anti-cancer agent, alone and in combination with our anti-PD-L1 antibody, and look forward to the advancement of CK-103 into a first-in-human Phase 1 trial expected to commence later this year."
The poster is available on the Publications page in the Pipeline section of Checkpoint’s website,
www.checkpointtx.com.